Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Legend-CART-201803-Ⅱ
Phase 1 small_molecule terminated
Quick answer
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for Lymphoma, B-Cell is a Phase 1 program (small_molecule) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Legend Biotech Corp
- Indication
- Lymphoma, B-Cell
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated